Allakos Stock News

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

Allakos Inc. (ALLK) closed the most recent trading day at $5.58, moving -0.18% from the previous trading session.

On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.

Related Stocks: ASLN , ANIP , ALLK , IMGN , BLU , LEGN , BCAB , APVO , NXTC ,

Within the last quarter, Allakos (NASDAQ:ALLK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 4 1 0 Last 30D 0 0

Within the last quarter, Allakos (NASDAQ: ALLK ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 4 1 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 3 1 0 3M Ago 1 0 0 0 0 According to 7 analyst offering 12-month price targets in the last 3 months, Allakos has an average price target of $40.43 with a high of $155.00 and a low of $8.00. Below is a summary of how these 7 analysts rated Allakos over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number … Full story available on Benzinga.com

The trading price of Allakos Inc. (NASDAQ:ALLK) closed lower on Monday, February 14, closing at $6.22, -3.27% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $6.12 and … Analysts Predict Allakos Inc. (NASDAQ: ALLK) To Loss -3067.2% From Current Levels. Read More »

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

Allakos Inc. (ALLK) closed at $6.54 in the latest trading session, marking no change from the prior day.

Allakos Inc. (ALLK) closed at $6.54 in the latest trading session, marking no change from the prior day.

In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.

In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.

ALLK stock is a gamble now even after falling about 85% off its 52-week high. Allakos' slide offers investors with a learning opportunity.

Allakos Inc (ALLK) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $426M. The stock is currently down 19.8% year-to-date, down 93.6% over the past 12 months, and down 74.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 77.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 236.3% The company's stock price performance over the past 12 months lags the peer average by 358.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.